|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In an orthotopic PDX model, animals receiving chemoimmunotherapy with an anti-GD2 antibody, GM-CSF, and a soluble IL15/IL15Rα complex had greater tumor regression than did those receiving chemotherapy alone (<i>P</i> = 0.012) or combined with anti-GD2 antibody and GM-CSF with (<i>P</i> = 0.016) or without IL2 (<i>P</i> = 0.035).
|
31455682 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that IL-2 gene transfer potentiates the antitumor activity of MRK16 against MDR tumors.
|
9439686 |
1997 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The 2nd gen dTc can be optimally activated to secrete larger amounts of cytokines such as IL2 and IFNγ than 1st gen and to proliferate more vigorously on PSMA-expressing tumor contact.
|
24174378 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicate that vaccination with cells releasing IL-2 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although this response occurred in a minority of the melanoma patients studied.
|
8930655 |
1996 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, a novel approach to gene therapy is being developed using direct tumor injection of cDNA, with a tumor specific promoter ligated to the IL-2 gene.
|
8039135 |
1994 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ACT of splenocytes from fully immunocompetent HLA-A2.1/K(b) mice transduced with a chimeric murine/human TCR specific for tyrosinase, together with lymphodepletion conditioning, dendritic cell (DC)-based vaccination, and high-dose interleukin-2 (IL-2), had profound antitumor activity against large established MHC- and antigen-matched tumors.
|
20624956 |
2010 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumour cell survival is supported by IL-2 and there is a skew towards CD8-positive T cells in the tumour environment, while the immune check-point protein PD-L1 is upregulated in the tumours.
|
29691476 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These cellular activations resulted in upregulation of host-protective cytokines IL-2, IL-12, IL-17, tumour necrosis factor-α and interferon-γ, and downregulation of IL-4, IL-10 and tumour growth factor-β.
|
29140228 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TIL were 20-fold more potent than LAK cells in eliminating the IL-2 expressing tumor cells in vitro.
|
8409397 |
1993 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The relationship between local treatment and tumour regression was supported by replacement of tumour cells by inflammatory cells in regressing lesions and marked induction of T and natural killer cell derived cytokines (IL-2, IL-4, IFNg ...) in post-therapeutic lesions analysed 28 days after the start of Vero-IL-2 administration.
|
11076653 |
2000 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Additionally, we found that coadministration of IL2 DNA with pcDNA3-CRT/E7 modified the tumor microenvironment by decreasing the population of regulatory T cells and myeloid-derived suppressor cells relative to that of CTLs.
|
28492521 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
There was a non-significant trend towards dose-dependent tumor uptake, with higher uptake at doses ≥20 mg. Biodistribution was dose- and CEA-independent with major accumulation in lymphoid tissue compatible with IL-2R binding.
|
29872502 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor cells genetically engineered to secrete IL-2 may therefore be promising candidates for tumor vaccines and may provide a new mode of cancer immunotherapy.
|
10697552 |
2000 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We assessed TIL expression of interleukin-2 (IL-2), IL-4, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), granulocyte-macrophage colony stimulating factor (GM-CSF), IL-10, and transforming growth factor-beta (TGF-beta), and tumor cell expression of IL-10 and TGF-beta in situ in 49 primary colon carcinomas and 20 metastases using immunohistochemistry.
|
8826937 |
1996 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This compares with tumor growth of 52% with interleukin-2 transduced C3L5 and over 85% with untransduced and control vector-transduced C3L5.
|
9270021 |
1997 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, this process was related to donor-derived T/B cells by improving the immune microenvironment in the tumor, as demonstrated by elevated levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), IL-6, IL-16, chemokine (C-X-C motif) ligand 10 (CXCL10), and CXCL11 and decreased levels of IL-10 and IL-4 at tumor sites.
|
31152624 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, treatment with IL-2 mutein reduces Treg cell numbers and impairs tumor growth in mice.
|
29618524 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A comparative quantitative biodistribution analysis with radio-labeled protein preparations revealed that a fractionated administration of L19-hIL2 could deliver comparable product doses to the tumor with decreased product concentration in blood and normal organs, compared to bolus injection.
|
31790729 |
2020 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tandem T cells secrete high levels of interleukin-2 and IFNgamma on tumor contact that first-generation T cells lacked, but secretion was exhaustible, suggesting a need for interleukin-2 supplementation in therapy even for these second-generation agents.
|
19088026 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition to this discovery, our laboratory has constructed monoclonal antibody/IL-2 fusion proteins that can target this potent cytokine directly to tumor for the immunotherapy of both solid and lymphoid malignancies.
|
12609842 |
2003 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A strong correlation (r = 0.997) was observed between tumor burden and the presence of soluble (serum) interleukin-2 receptor, a marker associated with a subset of human breast tumors.
|
9588898 |
1998 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Study of tumors from patients treated with interleukin-2 (IL-2) has suggested that response was unlikely in patients with tumors with papillary features or low carbonic anhydrase IX (CAIX) expression.
|
19402069 |
2009 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A 10- and 27-fold higher [<sup>18</sup>F]FB-IL-2 uptake was observed in tumors of mice receiving tumor irradiation alone or in combination with immunization, respectively.
|
28197364 |
2017 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This study explores the use of a liver-specific albumin promoter and a tumor-specific alpha-fetoprotein (AFP) enhancer to achieve the regulated expression of the cytokine interleukin-2/interferon alpha2b (IL-2/IFNalpha2b) fused gene for treatment of hepatocellular carcinoma (HCC).
|
10190313 |
1999 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In vivo studies showed a significant reduction of growth and the presence of an inflammatory infiltrate in transduced thyroid tumors expressing IL-2 alone, as compared with non-infected tumors.
|
12534360 |
2003 |